Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.

Pelvipharm SA provides preclinical research services. The company is specialized in pre clinical activities in the field of the pharmacological treatment of male and female sexual dysfunctions as well as non malignant diseases of the lower urinary tract with a special focus on urinary incontinence. The firm is engaged in urology and sexual medicine, basic research in physiology, neuro and cardio-vasucal pharmacology and pharmaco economy. The company is headquartered in Paris, France.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Semprae Laboratories, Inc. provides consumer products for female sexual health. The company was founded by Rachel Braun Scherl and Mary Wallace Jaensch in 2008 and is headquartered in San Diego, CA.

Cliovana Ltd. is a company headquartered in Toronto, ON, Canada, that provides cliovana treatments.\nThe company says this about itself: Cliovana is a completely non-invasive treatment that creates long-term increases in women's sexual responsiveness and orgasm frequency and intensity. The patented protocol is specifically designed for women and uses safe and proven sound wave technology to stimulate the body's natural processes, enhancing vascularization and neurogenesis in the clitoris, the area most critical to sexual satisfaction. The treatments are fast and pain-free, with no side effects and no downtime.

Lupin Laboratories Ltd. engages in pharmaceuticals sector. The company was founded on July 11, 1972 and is headquartered in Mumbai, India.

Medtronic AF Luxembourg SARL, part of Medtronic Plc, is a Luxembourgish company that functions as an investment holding company.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Laila Nutraceuticals Pvt Ltd., a subsidiary of Laila Group of Cos., is a company headquartered in Vijayawada, India, that manufactures and supplies dietary & nutritional products.

40 J's LLC provides medical instruments and technologies services. Its products include female sensuality gel and female sensuality gel custom formulations. The company is headquartered in Cincinnati, OH.

Behavioral Technology, Inc. operates as a medical device manufacturer. It offers surgical and medical instruments, dental equipment, and surgical appliances. The company was founded in 1994 and is headquartered in Salt Lake City, UT.

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure ("HF") and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure ("ADHF"), when the symptoms of HF become severe enough to require hospitalization.